The deal makes the platform available for application in Juno’s CAR-T and TCR-T programmes in oncology and other indications. Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) ...

Oxford, UK – 10 October 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which ...

(RTTNews) - Oxford Biomedica plc (OXB.L), a gene and cell therapy group, Monday said it has signed a new Licence and Supply Agreement or LSA with Arcellx, Inc. for LentiVector Platform for CAR-T ...

Lentivectors are potential vaccine delivery vehicles because they can efficiently transduce a variety of non-dividing cells, including antigen-presenting cells, and do not cause expression of extra ...

Oxford, UK – 3 August 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new Development, Manufacture ...

Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply ...

Oxford BioMedica Presents Ground-Breaking Evidence of Long-Term Duration of Therapeutic Expression in Patients from its Proprietary LentiVector® Gene Delivery Platform Oxford, UK - 6 May 2016: Oxford ...

Plant will be used to generate LentiVector gene delivery technology. Oxford BioMedica has acquired a manufacturing facility in Oxford, U.K., from RecipharmCobra Biologics for £1.9 million. The new ...

LONDON (Alliance News) - Gene and cell therapy company Oxford Biomedica PLC on Friday said two sets of test data have been released demonstrating long-term gene expression with its LentiVector ...

Oxford BioMedica has announced that it has signed a license agreement with the Carnegie Institution of Washington and the University of Massachusetts Medical School that grants the Company rights to ...

Oxford BioMedica announced that it has signed a licence agreement for its LentiVector technology with Merck & Co., Inc. The agreement allows Merck to use the company's proprietary LentiVector gene ...

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector ® Platform for Next Generation CAR-T Therapeutics Oxford, UK – 3 August 2020: Oxford ...